![Reid Huber](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Reid Huber
Patrimonio netto: 618 936 $ in data 31/12/2025
Profilo
Reid M.
Huber is currently Director at Tango Therapeutics Sub, Inc. since 2019, Director at Asher Biotherapeutics, Inc. since 2021, Director at Synnovation Therapeutics, Inc., Director at Terremoto Biosciences, Inc. since 2021, Non-Executive Director at Rapport Therapeutics, Inc. since 2022, and Partner at Third Rock Ventures LLC since 2018.
Former roles include Chief Executive Officer at Merida Biosciences, Inc., Chief Executive Officer & Director at MOMA Therapeutics, Inc. from 2020 to 2021, Independent Director at Bellicum Pharmaceuticals, Inc. from 2014 to 2024, Director at American Cancer Society, Inc., Director at Insitro, Inc., Independent Director at Cargo Therapeutics, Inc. from 2023 to 2025, Independent Director at Tango Therapeutics, Inc. from 2019 to 2023, Chief Scientific Officer & Executive VP at Incyte Corp.
from 2014 to 2018, and Principal Research Scientist at DuPont Pharmaceuticals Co. from 1998 to 2002.
Education includes an undergraduate degree from Murray State University (Kentucky) conferred in 1994 and a doctorate from Washington University School of Medicine conferred in 1998.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 12/09/2025 | 20.400 ( 0,04% ) | 618 936 $ | 31/12/2025 |
Ultime notizie su Reid Huber
Posizioni attive di Reid Huber
| Società | Posizione | Inizio |
|---|---|---|
| RAPPORT THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/02/2022 |
Synnovation Therapeutics, Inc.
 Synnovation Therapeutics, Inc. Develops novel small molecule targeted therapies for cancer patients | Direttore/Membro del Consiglio | - |
Terremoto Biosciences, Inc.
 Terremoto Biosciences, Inc. Operates as a drug development company | Direttore/Membro del Consiglio | 01/08/2021 |
Asher Biotherapeutics, Inc.
 Asher Biotherapeutics, Inc. Operates as a biotechnology company that develops immunotherapies | Direttore/Membro del Consiglio | 01/03/2021 |
Tango Therapeutics Sub, Inc.
 Tango Therapeutics Sub, Inc. Develops transformational new drugs for cancer patients | Direttore/Membro del Consiglio | 08/07/2019 |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures invests in companies located in the United States. The firm targets companies operating in the fields of healthcare sector. It provides financing for early stage capital requirements. The firm also acts as a lead investor. | Investitore di Private Equity | 01/12/2018 |
Precedenti posizioni note di Reid Huber
| Società | Posizione | Fine |
|---|---|---|
| CARO THERPAR | Direttore/Membro del Consiglio | 19/08/2025 |
| BELLICUM PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 23/02/2024 |
| TANGO THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/11/2023 |
| ░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Reid Huber
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 16 |
|---|---|
Incyte Corp.
 Incyte Corp. Engages in discovery, development and commercialization of proprietary therapeutics | |
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Focuses on discovering and developing novel cellular immunotherapies for various forms of cancer | Health Technology |
DuPont Pharmaceuticals Co.
 DuPont Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology Provides researches and develops pharmaceuticals and imaging products to treat diseases | Health Technology |
Murray State University (Kentucky)
 Murray State University (Kentucky) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
American Cancer Society, Inc.
 American Cancer Society, Inc. Miscellaneous Commercial ServicesCommercial Services Operates voluntary health organization for cancer research | Commercial Services |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures invests in companies located in the United States. The firm targets companies operating in the fields of healthcare sector. It provides financing for early stage capital requirements. The firm also acts as a lead investor. | Finance |
Washington University School of Medicine
 Washington University School of Medicine Functions as a College/University | |
Tango Therapeutics Sub, Inc.
Tango Therapeutics Sub, Inc. Develops transformational new drugs for cancer patients | |
Insitro, Inc.
 Insitro, Inc. Develops drug technology | |
Asher Biotherapeutics, Inc.
Asher Biotherapeutics, Inc. Operates as a biotechnology company that develops immunotherapies | |
MOMA Therapeutics, Inc.
 MOMA Therapeutics, Inc. Develops therapies for regenerative medicine employing injectable gel-based scaffolds designed to reprogram the function of cells in vivo and promote tissue regeneration | |
Tango Therapeutics, Inc.
 Tango Therapeutics, Inc. Operates as biotechnology company that engages in discovering and delivering precision cancer medicines | |
Cargo Therapeutics, Inc.
 Cargo Therapeutics, Inc. Engages in generation of adoptive cell therapies for cancer treatment | |
Synnovation Therapeutics, Inc.
Synnovation Therapeutics, Inc. Develops novel small molecule targeted therapies for cancer patients | |
Terremoto Biosciences, Inc.
Terremoto Biosciences, Inc. Operates as a drug development company | |
Rapport Therapeutics, Inc.
 Rapport Therapeutics, Inc. Operates as an clinical-stage biotechnology company that engages in discovery and development of medicines for neurological disorder |
